Apnimed, a late-stage drug developer focused on sleep apnea, has filed for an initial public offering of 10 million shares at a price range of $14 to $16 per share. The company is backed by Shionogi.
$160 million
Maximum amount Apnimed seeks to raise in the IPO
The company is seeking to raise as much as $160 million in its US initial public offering, according to the filing.